Rosuvastatin

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.

Telmisartan and Statin (Rosuvastatin or Atorvastatin) is a dual cardio-metabolic polypill formulation uniting an ARB with an HMG-CoA reductase inhibitor. Telmisartan controls systemic blood pressure and improves vascular endothelial function, while the statin potently reduces hepatic cholesterol synthesis, lowering LDL-C and apolipoprotein B while stabilizing atherosclerotic plaques. Indicated for co-existing essential hypertension and hyperlipidemia/dyslipidemia to mitigate cardiovascular morbidity and stroke.